Pinkpharma vaistinė, UAB - financials and debts

Company age: 11 y. 7 mo.

Update

Pinkpharma vaistinė - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue - - - - 8,878 465,266 1,325,836 1,002,320
Profit before tax - - - 0 - - - -
Net profit 0 0 0 0 -19,538 -114,244 -176,951 -143,764
Equity - - - 0 -39,538 -153,783 -330,734 -276,998
Liabilities 0 0 0 0 122,242 329,554 567,115 560,344
Non-current assets 0 0 0 0 66,605 60,185 158,119 138,396
Current assets 0 0 0 0 16,099 115,586 84,165 144,950
Total assets 0 0 0 0 82,704 175,771 242,284 283,346
Taxes paid
STI taxes - - - - - - 41,255 22,581
Social insurance contributions - - - - - 10,644 28,217 25,409
Financial indicators
Revenue change y/y - - - - - +5140.7% +185.0% -24.4%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. - - - - -23.6% -65.0% -73.0% -50.7%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. - - - - - - - -
Profit margin Net profit margin. Shows the overall profitability of the company. - - - - -220.1% -24.6% -13.3% -14.3%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. - - - - - - - -
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. - - - - - - - -
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. - - - - 2,959 126,890 227,287 169,405

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Pinkpharma vaistinė - Social security debts

The amount of overdue SODRA debt for the company Pinkpharma vaistinė as of the last working day is: 41 €

From To Debt, €
2026-09-16 2026-09-17 41.20
2026-07-23 2026-07-26 1.57
2026-06-16 2026-06-25 1626.15
2026-04-01 2026-04-15 12.02
2026-02-18 2026-03-01 154.26
2025-09-16 2025-09-16 1487.80
2025-08-28 2025-08-29 1129.62
2025-08-19 2025-08-24 1129.62
2024-10-16 2024-10-20 2060.29
2024-01-16 2024-01-25 112.05
2023-11-16 2023-11-20 6.81
2023-10-17 2023-11-13 6.81
2023-09-18 2023-10-15 6.77
2023-08-17 2023-09-12 5.07
2023-07-18 2023-08-10 2.58
2023-06-16 2023-06-21 5.72
2023-05-16 2023-06-14 2.86
2023-05-02 2023-05-03 773.70
2023-04-18 2023-04-28 773.70
2023-02-17 2023-02-27 598.34
2022-10-18 2022-11-14 0.25

Pinkpharma vaistinė - VMI tax arrears

From To Overdue, €
2026-07-30 2026-08-10 0.53
2026-02-27 2026-03-11 2.76
2026-02-21 2026-02-26 1.13
2026-02-13 2026-02-20 323.78
2026-01-29 2026-02-03 0.37
2025-11-30 2025-12-11 1.69
2025-11-28 2025-11-29 1275.53
2025-11-25 2025-11-27 1.69
2025-10-30 2025-11-12 0.27
2025-07-29 2025-08-06 0.93
2025-07-28 2025-07-28 18102.93
2025-04-18 2025-04-18 3850.0
2025-01-10 2025-01-13 1594.37
2024-12-03 2024-12-19 0.97
2024-10-12 2024-10-15 0.1

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Pinkpharma vaistine, UAB (company code 303572529) is a Private Limited Liability Company active in the wholesale of wood, construction materials and sanitary equipment. In the latest financial year, 2025, revenue amounted to €1.00M, down 24.4% year on year after reaching €1.33M in 2024. Over the 2-year period from 2023 to 2025, revenue still increased by 115.4%, showing a strong longer-term expansion despite the latest decline. The company remained loss-making, reporting a net loss of €143.8K in 2025 versus a loss of €177.0K in 2024 and €114.2K in 2023. The 2025 profit margin was -14.3%. The balance sheet shows total assets of €283.3K, equity of -€277.0K and liabilities of €560.3K, indicating a highly leveraged and balance-sheet-stressed position. Asset turnover was 3.54x, and revenue per employee reached €200.5K, while profit per employee was -€28.8K. Return measures remain weak, with the negative equity position distorting profitability on equity.